Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University scientist have discovered the molecular ‘first responder’ which detects disturbances in the flow of blood through the arteries, and responds by encouraging the formation of plaques which can lead to serious problems, including heart attack, stroke and even death.

Atherosclerosis, Cholesterol plaque in artery. 3d illustration

The study, published in the journal Nature, found that mice without this molecule in its right shape don’t have clogged arteries, even when they eat an unhealthy high fat diet.

Atherosclerosis is a potentially fatal disease where fatty plaques clog up the arteries supplying blood to the heart, brain and other organs. These plaques cause the arteries to narrow and can increase the risk of blood clots that could block blood flow to the heart or brain, making it more likely that patients with atherosclerosis will suffer from heart attacks or strokes.

But scientists have known for over 200 years that the plaques don’t form just anywhere in the arteries – they are much more likely to form where the arteries curve or split, causing whorls and eddies in the blood flowing through them.

Read the full story on the University of Oxford website

Similar stories

Human challenge trial launches to study immune response to COVID-19

Clinical Trials Coronavirus COVID-19 General

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.